What's Happening?
Codexis, a company specializing in enzymatic solutions for manufacturing complex oligonucleotide therapeutics, has announced significant advancements in RNA therapeutic manufacturing at the TIDES USA 2026 conference in Boston. The company introduced its
ECO Synthesis® Manufacturing Platform, which now allows for precise stereochemical control in the production of siRNA. This development addresses key industry challenges related to scalability and sustainability. Codexis demonstrated full-length siRNA synthesis with controlled phosphorothioate stereochemistry, which is crucial for the efficacy and quality of oligonucleotide therapeutics. Additionally, the company has developed a method to initiate enzymatic RNA synthesis from a single nucleotide, eliminating the need for chemically-synthesized starter oligonucleotides. This innovation is expected to enhance the efficiency and scalability of siRNA production.
Why It's Important?
The advancements by Codexis are significant for the RNA therapeutics industry, which is increasingly focused on improving drug potency and manufacturing efficiency. Stereochemical control is essential for optimizing the performance of RNA therapeutics, potentially leading to novel dosage forms and higher concentrations of active pharmaceutical ingredients. By eliminating the need for starter oligonucleotides, Codexis enhances the scalability and environmental sustainability of RNA manufacturing. The company's ECO Synthesis platform has demonstrated a more than 50% reduction in global warming potential compared to traditional methods, highlighting its commitment to sustainable practices. These innovations could lead to more effective and accessible RNA-based treatments, benefiting both manufacturers and patients.
What's Next?
Codexis plans to continue advancing its ECO Synthesis platform as part of its strategy to develop scalable manufacturing solutions for complex RNA therapeutics. The company aims to further innovate in the field of biocatalytic enzymes to enhance oligonucleotide medicine production. As the RNA therapeutics field matures, the importance of ligation and stereochemical control is expected to grow, driving further research and development. Codexis's focus on sustainability and efficiency positions it as a leader in the industry, potentially influencing other companies to adopt similar practices.
